WHO Report Highlights Progress and Challenges in Global Fight Against HIV, Hepatitis and STIs

The World Health Organization released a comprehensive assessment report during the 26th International AIDS Conference (AIDS 2026), evaluating global progress toward the 2030 targets for HIV, viral hepatitis, and sexually transmitted infections. According to the document, an estimated 32 million people living with HIV were receiving antiretroviral therapy by the end of 2025, while new infections fell by 42% and AIDS-related deaths dropped by 57% since 2010. However, persistent funding reductions, humanitarian emergencies, and systemic barriers continue to threaten these gains across multiple regions.

Key Clinical Takeaways:

• Global HIV treatment reached 32 million individuals by late 2025, though 9 million people still lack access to life-saving regimens.
• Annual hepatitis B infections decreased by 32% since 2015, yet hepatitis B mortality increased by 17% over the same period.
• Rising sexually transmitted infection incidence and growing antimicrobial resistance in gonorrhoea strains threaten clinical standards of care.

The assessment, published ahead of World Hepatitis Day, highlights a fractured global landscape where scientific advancements in prevention and treatment clash with systemic funding disruptions. Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, noted that while the data demonstrates the potential of targeted health investments, progress remains fragile in the face of ongoing inequalities.

Epidemiological metrics for viral hepatitis present a similarly complex picture. Since 2015, global hepatitis C-related deaths have fallen by 12%, and hepatitis B incidence dropped by nearly a third. Despite these positive trends, viral hepatitis claimed approximately 1.3 million lives in 2024. The report attributes rising mortality primarily to low diagnostic and treatment coverage for chronic hepatitis B, despite the availability of potent antiviral drugs capable of halting disease progression and reducing morbidity.

The response to sexually transmitted infections remains off track due to rising case numbers and emerging pharmacological hurdles. While national policies have successfully improved syphilis screening during pregnancy and lifted human papillomavirus vaccination coverage modestly, gonorrhoea strains exhibit escalating antimicrobial resistance. To counter these vulnerabilities, the WHO emphasized the clinical utility of long-acting prevention technologies, such as twice-yearly injectable lenacapavir for HIV and doxycycline post-exposure prophylaxis for bacterial sexually transmitted infections.

Dr. Tereza Kasaeva, Director of WHO’s Department for HIV, TB, Hepatitis and STIs, emphasized that the assessment serves as a practical guide for the remaining years of the strategy period. Alongside the report, the agency published consolidated HIV service delivery guidelines and updated surveillance frameworks designed to optimize routine data collection and clinical decision-making.

Achieving the 2030 elimination targets will depend heavily on service integration within primary health care frameworks, pairing disease-specific interventions with maternal, child, and noncommunicable disease management. As funding dynamics shift and new diagnostic tools scale globally, maintaining resilient health systems remains the primary defense against resurgence.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.